We now demonstrated that KCa3.1 inhibition or silencing significantly enhances the anti-proliferative effects of the alkylating agent TMZ, increasing the number of apoptotic cells and reducing cell viability, suggesting KCa3.1 as a key therapeutic target for glioma. The gene discussed is KCNN4; the disease is glioma.